Literature DB >> 30016400

Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling.

Sirirat Surinkaew1,2, Mona Aflaki1,3, Abhijit Takawale1,3, Yu Chen1, Xiao-Yan Qi1, Marc-Antoine Gillis1, Yan-Fen Shi1, Jean-Claude Tardif1, Nipon Chattipakorn4, Stanley Nattel1,3,5.   

Abstract

Aims: Heart failure (HF) produces left atrial (LA)-selective fibrosis and promotes atrial fibrillation. HF also causes adrenergic activation, which contributes to remodelling via a variety of signalling molecules, including the exchange protein activated by cAMP (Epac). Here, we evaluate the effects of Epac1-signalling on LA fibroblast (FB) function and its potential role in HF-related atrial remodelling. Methods and results: HF was induced in adult male mongrel dogs by ventricular tachypacing (VTP). Epac1-expression decreased in LA-FBs within 12 h (-3.9-fold) of VTP onset. The selective Epac activator, 8-pCPT (50 µM) reduced, whereas the Epac blocker ESI-09 (1 µM) enhanced, collagen expression in LA-FBs. Norepinephrine (1 µM) decreased Epac1-expression, an effect blocked by prazosin, and increased FB collagen production. The β-adrenoceptor (AR) agonist isoproterenol increased Epac1 expression, an effect antagonized by ICI (β2-AR-blocker), but not by CGP (β1-AR-blocker). β-AR-activation with isoproterenol decreased collagen expression, an effect mimicked by the β2-AR-agonist salbutamol and blocked by the Epac1-antagonist ESI-09. Transforming growth factor-β1, known to be activated in HF, suppressed Epac1 expression, an effect blocked by the Smad3-inhibitor SIS3. To evaluate effects on atrial fibrosis in vivo, mice subjected to myocardial infarction (MI) received the Epac-activator Sp-8-pCPT or vehicle for 2 weeks post-MI; Sp-8-pCPT diminished LA fibrosis and attenuated cardiac dysfunction. Conclusions: HF reduces LA-FB Epac1 expression. Adrenergic activation has complex effects on FBs, with α-AR-activation suppressing Epac1-expression and increasing collagen expression, and β2-AR-activation having opposite effects. Epac1-activation reduces cardiac dysfunction and LA fibrosis post-MI. Thus, Epac1 signalling may be a novel target for the prevention of profibrillatory cardiac remodelling.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30016400      PMCID: PMC6302269          DOI: 10.1093/cvr/cvy173

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  48 in total

Review 1.  Structural and functional characterisation of cardiac fibroblasts.

Authors:  Patrizia Camelliti; Thomas K Borg; Peter Kohl
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

2.  Identification of G protein-coupled signaling pathways in cardiac fibroblasts: cross talk between G(q) and G(s).

Authors:  J G Meszaros; A M Gonzalez; Y Endo-Mochizuki; S Villegas; F Villarreal; L L Brunton
Journal:  Am J Physiol Cell Physiol       Date:  2000-01       Impact factor: 4.249

3.  EPAC activation inhibits acetaldehyde-induced activation and proliferation of hepatic stellate cell via Rap1.

Authors:  Yan Yang; Feng Yang; Xiaojuan Wu; Xiongwen Lv; Jun Li
Journal:  Can J Physiol Pharmacol       Date:  2015-11-19       Impact factor: 2.273

Review 4.  Epac: defining a new mechanism for cAMP action.

Authors:  Martijn Gloerich; Johannes L Bos
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

5.  Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences.

Authors:  Brett Burstein; Eric Libby; Angelino Calderone; Stanley Nattel
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

Review 6.  Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation.

Authors:  Brett Burstein; Stanley Nattel
Journal:  J Am Coll Cardiol       Date:  2008-02-26       Impact factor: 24.094

7.  Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment.

Authors:  B Bhambi; M Eghbali
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

Review 8.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 9.  Cyclic AMP Sensor EPAC Proteins and Their Role in Cardiovascular Function and Disease.

Authors:  Frank Lezoualc'h; Loubina Fazal; Marion Laudette; Caroline Conte
Journal:  Circ Res       Date:  2016-03-04       Impact factor: 17.367

10.  Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: a novel therapeutic approach for cardiac fibrosis.

Authors:  David Lu; Nakon Aroonsakool; Utako Yokoyama; Hemal H Patel; Paul A Insel
Journal:  Mol Pharmacol       Date:  2013-10-01       Impact factor: 4.436

View more
  12 in total

Review 1.  The role of ADRB2 gene polymorphisms in malignancies.

Authors:  Yaqian Wang; Shujuan Jiang
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

Review 2.  Physiological roles of mammalian transmembrane adenylyl cyclase isoforms.

Authors:  Katrina F Ostrom; Justin E LaVigne; Tarsis F Brust; Roland Seifert; Carmen W Dessauer; Val J Watts; Rennolds S Ostrom
Journal:  Physiol Rev       Date:  2021-10-26       Impact factor: 37.312

Review 3.  Cardiac cAMP-PKA Signaling Compartmentalization in Myocardial Infarction.

Authors:  Anne-Sophie Colombe; Guillaume Pidoux
Journal:  Cells       Date:  2021-04-16       Impact factor: 6.600

Review 4.  Therapeutic targets for cardiac fibrosis: from old school to next-gen.

Authors:  Joshua G Travers; Charles A Tharp; Marcello Rubino; Timothy A McKinsey
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

5.  Chronic isoprenaline/phenylephrine vs. exclusive isoprenaline stimulation in mice: critical contribution of alpha1-adrenoceptors to early cardiac stress responses.

Authors:  Matthias Dewenter; Jianyuan Pan; Laura Knödler; Niklas Tzschöckel; Julian Henrich; Julio Cordero; Gergana Dobreva; Susanne Lutz; Johannes Backs; Thomas Wieland; Christiane Vettel
Journal:  Basic Res Cardiol       Date:  2022-03-14       Impact factor: 12.416

Review 6.  Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Authors:  Guangling Li; Jing Yang; Demei Zhang; Xiaomei Wang; Jingjing Han; Xueya Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-25

7.  PU.1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-β1/Smads pathway activation.

Authors:  Juan Hu; Jing-Jing Zhang; Li Li; Shan-Ling Wang; Hai-Tao Yang; Xian-Wei Fan; Lei-Ming Zhang; Guang-Ling Hu; Hai-Xia Fu; Wei-Feng Song; Li-Jie Yan; Jing-Jing Liu; Jin-Tao Wu; Bin Kong
Journal:  J Cell Mol Med       Date:  2021-06-15       Impact factor: 5.310

Review 8.  The Roles of Noncardiomyocytes in Cardiac Remodeling.

Authors:  Dan Yang; Han-Qing Liu; Fang-Yuan Liu; Nan Tang; Zhen Guo; Shu-Qing Ma; Peng An; Ming-Yu Wang; Hai-Ming Wu; Zheng Yang; Di Fan; Qi-Zhu Tang
Journal:  Int J Biol Sci       Date:  2020-07-02       Impact factor: 6.580

Review 9.  The Role of Cyclic AMP Signaling in Cardiac Fibrosis.

Authors:  Marion Delaunay; Halima Osman; Simon Kaiser; Dario Diviani
Journal:  Cells       Date:  2019-12-26       Impact factor: 6.600

Review 10.  The Epac1 Protein: Pharmacological Modulators, Cardiac Signalosome and Pathophysiology.

Authors:  Marion Bouvet; Jean-Paul Blondeau; Frank Lezoualc'h
Journal:  Cells       Date:  2019-11-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.